Wall Street brokerages expect Horizon Pharma PLC (NASDAQ:HZNP) to post $0.22 earnings per share for the current quarter, according to Zacks. Two analysts have issued estimates for Horizon Pharma’s earnings, with estimates ranging from $0.19 to $0.24. Horizon Pharma reported earnings per share of $0.66 in the same quarter last year, which suggests a negative year over year growth rate of 66.7%. The company is expected to announce its next earnings report on Monday, February 26th.
On average, analysts expect that Horizon Pharma will report full year earnings of $1.09 per share for the current financial year, with EPS estimates ranging from $1.04 to $1.13. For the next financial year, analysts expect that the company will post earnings of $1.28 per share, with EPS estimates ranging from $1.04 to $1.45. Zacks’ earnings per share calculations are an average based on a survey of analysts that cover Horizon Pharma.
Horizon Pharma (NASDAQ:HZNP) last announced its earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.22 by $0.04. Horizon Pharma had a positive return on equity of 20.22% and a negative net margin of 45.28%. The company had revenue of $271.60 million for the quarter, compared to analyst estimates of $259.74 million. During the same period in the prior year, the company posted $0.70 EPS. The firm’s quarterly revenue was up 30.1% compared to the same quarter last year.
A number of institutional investors have recently bought and sold shares of HZNP. Advantage Investment Management LLC grew its stake in Horizon Pharma by 164.8% during the 3rd quarter. Advantage Investment Management LLC now owns 7,874 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 4,900 shares during the last quarter. Bank of Montreal Can boosted its stake in shares of Horizon Pharma by 16.3% in the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 1,378 shares during the last quarter. Sheaff Brock Investment Advisors LLC boosted its stake in shares of Horizon Pharma by 5.0% in the second quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 500 shares during the last quarter. Family Management Corp purchased a new stake in shares of Horizon Pharma in the second quarter worth about $131,000. Finally, Brown Advisory Inc. purchased a new stake in shares of Horizon Pharma in the third quarter worth about $145,000. Institutional investors and hedge funds own 86.58% of the company’s stock.
Horizon Pharma (HZNP) opened at $15.37 on Friday. Horizon Pharma has a 1 year low of $9.45 and a 1 year high of $18.31. The stock has a market capitalization of $2,490.00, a PE ratio of -5.06, a P/E/G ratio of 0.73 and a beta of 1.30. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.52 and a current ratio of 1.64.
TRADEMARK VIOLATION WARNING: “Horizon Pharma PLC (HZNP) Expected to Post Earnings of $0.22 Per Share” was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.chaffeybreeze.com/2018/01/05/horizon-pharma-plc-hznp-expected-to-post-earnings-of-0-22-per-share.html.
About Horizon Pharma
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.